Concordance index: Surrogacy of progression-free survival for overall survival

Yiwei Fan, Guosheng Yin*

*此作品的通讯作者

科研成果: 期刊稿件文章同行评审

5 引用 (Scopus)

摘要

In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment till death) are the focus of statistical analysis in comparison of two treatment arms. It is often argued that PFS may serve as a surrogate endpoint for OS, while the validity of such surrogacy is still under debates in different types of cancer. In practice, one may observe a significant difference in PFS but no significant difference in OS; or vice versa. We provide a concordance index (C-index) to measure the degree of concordance between PFS and OS, and elaborate on the PFS vs OS discrepancies using the C-index using simulation studies and real trial analysis.

源语言英语
文章编号106353
期刊Contemporary Clinical Trials
104
DOI
出版状态已出版 - 5月 2021
已对外发布

指纹

探究 'Concordance index: Surrogacy of progression-free survival for overall survival' 的科研主题。它们共同构成独一无二的指纹。

引用此

Fan, Y., & Yin, G. (2021). Concordance index: Surrogacy of progression-free survival for overall survival. Contemporary Clinical Trials, 104, 文章 106353. https://doi.org/10.1016/j.cct.2021.106353